SOLICITATION NOTICE
Q -- Formalin Fixed Tissue Blocks and Melanoma Lesion Pathology Reports
- Notice Date
- 8/15/2012
- Notice Type
- Presolicitation
- NAICS
- 541380
— Testing Laboratories
- Contracting Office
- Department of Health and Human Services, National Institutes of Health, National Cancer Institute, Office of Acquisitions, 6120 Executive Blvd., EPS Suite 600, Rockville, Maryland, 20852
- ZIP Code
- 20852
- Solicitation Number
- NCI-120179-LG
- Archive Date
- 9/14/2012
- Point of Contact
- Laura Glockner, Phone: 3014968607
- E-Mail Address
-
laura.glockner@nih.gov
(laura.glockner@nih.gov)
- Small Business Set-Aside
- N/A
- Description
- Department of Health and Human Services, National Institutes of Health, National Cancer Institute, Office of Acquisitions, 6120 Executive Boulevard, EPS Suite 600, Room 6070, Rockville, MD 20852, UNITED STATES. Description The National Cancer Institute (NCI), Division of Cancer Epidemiology and Genetics (DCEG), Genetic Epidemiology Branch (GEB), plans to procure on a sole source basis services from University of L'Aquila, Department of Biotechnological and Applied Clinical Sciences, Via Vetoio, Coppito 2, 67100, l'Aquila, Italy, for the collection of formalin fixed tissue blocks and melanoma lesion pathology reports. This acquisition will be processed in accordance with simplified acquisition procedures in FAR Part 13.106 (b)(1). The North American Industry Classification System code is 541380 the business size standard is $14.0 million. Only one award will be made as a result of this solicitation. This will be awarded as a firm fixed price type contract. Period of Performance: Performance shall be from September 28, 2012 - September 27, 2013 with one (1) twelve month option period. It has been determined that there is no opportunity to acquire green products or services under this contract. The Division of Cancer Epidemiology and Genetics (DCEG) is an intramural research program of the National Cancer Institute (NCI), National Institutes of Health (NIH) that conducts population and multidisciplinary research to discover the genetic and environmental determinants of cancer and new approaches to cancer prevention. The GEB has been investigating epidemiological and genetic factors associated with melanoma risk in a case-control study of melanoma conducted at the University of L'Aquila. The purpose of this requirement is to support the collection of formalin fixed tissue blocks and related pathology reports and clinical data from melanoma cases previously examined for epidemiological and genetic variant associations with melanoma risk. The Genetic Epidemiology Branch (GEB) has successfully conducted an analysis of epidemiological and genetic factors associated with melanoma risk in a case-control study of melanoma conducted at the University of L'Aquila, Department of Biotechnological and Applied Clinical Sciences. The GEB needs to collect melanoma tissue blocks from the same melanoma cases from which the branch has examined epidemiological and genetic risk factors, in order to correlate these data with molecular changes across tumors. The Department of Biotechnological and Applied Clinical Sciences has great experience in following screening criteria for nevi and pigmentation characteristics and epidemiological data collection. The Department's scientists have been trained in the recognition of dysplastic nevi and melanoma as well as pathological features of melanoma lesions and can ensure continuity in the research. The Department of Biotechnological and Applied Clinical Sciences also has surgeons that can verify the melanoma diagnoses by reviewing the pathology reports from the pathologists of the L'Aquila University. In addition, the Department's scientists have expertise in the practical aspects involved in the management of data, clinical forms, informed consents, and biospecimens according to NCI standard and operating procedures and will ensure optimal quality of the collected data. Finally, the Department of Biotechnological and Applied Clinical Sciences has access to medical and pathological records from the same melanoma patients previously analyzed at NCI, which is pivotal to the completion of this project. Based upon these factors the Department of Biotechnological and Applied Clinical Sciences at the University of L'Aquila is the only know contractor that can fulfill the requirements of this contract. This is not a solicitation for competitive quotations. However, if any interested party believes they can meet the above requirement, they may submit a statement of capabilities. All information furnished must be in writing and must contain sufficient detail to allow the NCI to determine if it can meet the above unique specifications described herein. An original and one copy of the capability statement must be received in the NCI Office of Acquisition on or before 11:00 AM EST on August 30, 2012. No electronic capability statements will be accepted (i.e. email or fax) an original and one copy must be sent to the NCI Office of Acquisition to the address stated above. All questions must be in writing and can be faxed (301) 402-4513 or emailed to Laura Glockner, Contract Specialist at laura.glockner@nih.gov. A determination by the Government not to compete this proposed contract based upon responses to this notice is solely within the discretion of the Government. Information received will be considered solely for the purpose of determining whether to conduct a competitive procurement. In order to receive an award, contractors must have valid registration and certification in the Central Contractor Registration (CCR) and the Online Representations and Certifications Applications (ORCA) through SAM.gov. No collect calls will be accepted. Please reference solicitation number NCI-120179-LG on all correspondence.
- Web Link
-
FBO.gov Permalink
(https://www.fbo.gov/spg/HHS/NIH/RCB/NCI-120179-LG/listing.html)
- Record
- SN02840709-W 20120817/120816000432-f8d01d85a25bad17917904f0f2197984 (fbodaily.com)
- Source
-
FedBizOpps Link to This Notice
(may not be valid after Archive Date)
| FSG Index | This Issue's Index | Today's FBO Daily Index Page |